Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS).
Dutch Childhood Cancer Survivor Study
Dutch LATER METS
childhood cancer survivor
metabolic syndrome
methodology
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
27 Jan 2021
27 Jan 2021
Historique:
received:
09
06
2020
accepted:
10
11
2020
revised:
18
08
2020
pubmed:
5
8
2020
medline:
5
8
2020
entrez:
5
8
2020
Statut:
epublish
Résumé
Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis, and preventive strategies is of importance to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no national cohort studies on the prevalence and determinants of metabolic syndrome in childhood cancer survivors, including biomarkers and genetic predisposition, are available. The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of metabolic syndrome and its separate components, and 2) the potential diagnostic and predictive value of additional biomarkers for surveillance of metabolic syndrome in the national cohort of adult long-term survivors of childhood cancer. This is a cross-sectional study based on recruitment of all survivors treated in the Netherlands between 1963 and 2002. Metabolic syndrome will be classified according to the definitions of the third Adult Treatment Panel Report of the National Cholesterol Education Program as well as the Joint Interim Statement and compared to reference data. Dual-energy x-ray absorptiometry scans were performed to assess body composition in more detail. The effect of patient characteristics, previous treatment, and genetic variation on the risk of metabolic syndrome will be assessed. The diagnostic and predictive value of novel biomarkers will be tested. Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors from 7 pediatric oncology hospitals have participated. From July 2020, biomarker testing, single nucleotide polymorphism analysis, and data analysis will be performed. The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of metabolic syndrome and the diagnostic value of biomarkers in childhood cancer survivors. The results of this study will be used to optimize surveillance guidelines for metabolic syndrome in survivors based on enhanced risk stratification and screening strategies. This will improve diagnosis of metabolic syndrome and prevent complications. DERR1-10.2196/21256.
Sections du résumé
BACKGROUND
BACKGROUND
Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis, and preventive strategies is of importance to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no national cohort studies on the prevalence and determinants of metabolic syndrome in childhood cancer survivors, including biomarkers and genetic predisposition, are available.
OBJECTIVE
OBJECTIVE
The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of metabolic syndrome and its separate components, and 2) the potential diagnostic and predictive value of additional biomarkers for surveillance of metabolic syndrome in the national cohort of adult long-term survivors of childhood cancer.
METHODS
METHODS
This is a cross-sectional study based on recruitment of all survivors treated in the Netherlands between 1963 and 2002. Metabolic syndrome will be classified according to the definitions of the third Adult Treatment Panel Report of the National Cholesterol Education Program as well as the Joint Interim Statement and compared to reference data. Dual-energy x-ray absorptiometry scans were performed to assess body composition in more detail. The effect of patient characteristics, previous treatment, and genetic variation on the risk of metabolic syndrome will be assessed. The diagnostic and predictive value of novel biomarkers will be tested.
RESULTS
RESULTS
Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors from 7 pediatric oncology hospitals have participated. From July 2020, biomarker testing, single nucleotide polymorphism analysis, and data analysis will be performed.
CONCLUSIONS
CONCLUSIONS
The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of metabolic syndrome and the diagnostic value of biomarkers in childhood cancer survivors. The results of this study will be used to optimize surveillance guidelines for metabolic syndrome in survivors based on enhanced risk stratification and screening strategies. This will improve diagnosis of metabolic syndrome and prevent complications.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/21256.
Identifiants
pubmed: 32750002
pii: v10i1e21256
doi: 10.2196/21256
pmc: PMC7875697
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e21256Informations de copyright
©Vincent Pluimakers, Marta Fiocco, Jenneke van Atteveld, Monique Hobbelink, Dorine Bresters, Eline Van Dulmen-den Broeder, Margriet Van der Heiden-van der Loo, Geert O Janssens, Leontien Kremer, Jacqueline Loonen, Marloes Louwerens, Helena Van der Pal, Cécile Ronckers, Hanneke Van Santen, Birgitta Versluys, Andrica De Vries, Marry Van den Heuvel-Eibrink, Sebastian Neggers. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 27.01.2021.
Références
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Blood. 2011 Apr 28;117(17):4442-8
pubmed: 21278355
Eur J Intern Med. 2016 Apr;29:3-8
pubmed: 26703429
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
Annu Rev Med. 2018 Jan 29;69:247-262
pubmed: 29029584
J Am Coll Cardiol. 2005 Dec 6;46(11):1978-85
pubmed: 16325028
Bioinformatics. 2003 Jan;19(1):149-50
pubmed: 12499305
Eur J Cancer. 2014 Apr;50(6):1169-75
pubmed: 24507548
Pediatr Blood Cancer. 2015 Nov;62(11):1992-9
pubmed: 25989749
Eur J Endocrinol. 2013 May 07;168(6):905-12
pubmed: 23557987
Eur J Cancer. 2013 Feb;49(3):668-75
pubmed: 23036851
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Lancet Oncol. 2010 Feb;11(2):193-203
pubmed: 20152771
J Clin Oncol. 2012 Nov 10;30(32):3991-7
pubmed: 23032628
Crit Rev Oncol Hematol. 2019 Jan;133:129-141
pubmed: 30661649
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
Sci Rep. 2018 Aug 1;8(1):11529
pubmed: 30068918
PLoS One. 2012;7(8):e43269
pubmed: 22905245
J Clin Oncol. 2009 May 10;27(14):2328-38
pubmed: 19332714
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
Biol Blood Marrow Transplant. 2018 Mar;24(3):622-626
pubmed: 29197678
Int J Cancer. 2016 Jul 15;139(2):322-33
pubmed: 26950898
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Am J Clin Nutr. 2018 Jan 1;107(1):3-11
pubmed: 29381792
Clin Endocrinol (Oxf). 2015 Jan;82(1):59-67
pubmed: 25132503
Indian J Cancer. 2015 Apr-Jun;52(2):219-23
pubmed: 26853412
Crit Rev Oncol Hematol. 2018 Jun;126:154-167
pubmed: 29759558
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Bone Marrow Transplant. 2015 Nov;50(11):1438-44
pubmed: 26191949
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Arch Intern Med. 2009 Aug 10;169(15):1381-8
pubmed: 19667301
Ann Oncol. 2013 Mar;24(3):749-55
pubmed: 23131388
PLoS One. 2012;7(12):e52237
pubmed: 23251703
Eur J Cancer. 2019 Mar;110:86-97
pubmed: 30772657
JAMA. 2010 Jul 14;304(2):172-9
pubmed: 20628130
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Diabetes Care. 1991 Mar;14(3):173-94
pubmed: 2044434
Nat Protoc. 2010 Sep;5(9):1564-73
pubmed: 21085122
Circulation. 2012 May 22;125(20):2469-78
pubmed: 22539783
Bioinformatics. 2016 May 1;32(9):1423-6
pubmed: 27153000
Eur J Endocrinol. 2017 Apr;176(4):R183-R203
pubmed: 28153840
Pediatr Blood Cancer. 2013 Dec;60(12):1922-8
pubmed: 23913590
Cancer. 2014 Sep 1;120(17):2742-50
pubmed: 25070001
Cancer. 2015 Dec 1;121(23):4197-204
pubmed: 26287726
Biol Blood Marrow Transplant. 2017 Mar;23(3):475-482
pubmed: 28040534
J Clin Oncol. 2012 May 1;30(13):1429-37
pubmed: 22473161
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1705-1713
pubmed: 29167278
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
Cancer. 2015 Jun 15;121(12):2036-43
pubmed: 25728221
Eur J Cancer. 2012 May;48(8):1159-66
pubmed: 22513228
BMC Cancer. 2017 Nov 10;17(1):751
pubmed: 29126409
Biol Blood Marrow Transplant. 2010 Dec;16(12):1674-81
pubmed: 20685399
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Clin Oncol. 2016 Sep 20;34(27):3240-7
pubmed: 27382091
J Clin Oncol. 2013 Nov 1;31(31):3906-13
pubmed: 24062395
Lancet Oncol. 2012 Oct;13(10):1002-10
pubmed: 22921663
Diabetes. 1988 Dec;37(12):1595-607
pubmed: 3056758
Haematologica. 2016 Dec;101(12):1603-1610
pubmed: 27515247
Br J Haematol. 2014 May;165(3):364-74
pubmed: 24467690
Metabolism. 2006 Nov;55(11):1546-50
pubmed: 17046559
J Exp Clin Cancer Res. 2011 Jun 01;30:64
pubmed: 21631924
Endocr Dev. 2009;15:1-24
pubmed: 19293601
Eur Respir J. 2011 Jan;37(1):150-6
pubmed: 20525717
Cochrane Database Syst Rev. 2019 Mar 11;3:CD008944
pubmed: 30855726
Cancer. 2015 Jul 1;121(13):2262-70
pubmed: 25963547
Eur J Prev Cardiol. 2015 Jun;22(6):762-70
pubmed: 24691151